LAT8881 / Lateral Pharma - LARVOL DELTA

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. (PubMed, Front Endocrinol (Lausanne)) - "The agents most commonly encountered in clinical practice and online self-administration protocols include growth hormone-releasing hormone (GHRH) analogues (e.g., sermorelin, tesamorelin, CJC-1295 with Drug Affinity Complex [DAC], CJC-1295 without DAC), growth hormone secretagogues (GHS; e.g., growth hormone-releasing peptide-2 (GHRP-2), growth hormone-releasing peptide-6 (GHRP-6), hexarelin, ipamorelin), the growth hormone (GH) fragment - AOD9604 (hGH 176-191), and insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)). We summarise structural characteristics, pharmacologic effects, and commonly reported dosing patterns, and we synthesise clinically relevant adverse effects with particular attention to hormonal imbalance, endocrine-metabolic risk, and biologically plausible but unproven mitogenic concerns. Finally, we propose a clinically oriented assessment algorithm to support exposure history..."

Journal • Review • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Pain • IGF1

Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. (PubMed, Analyst) - "The method was successfully applied to samples containing sub-ng levels of ibutamoren, confirming that the analytical procedure presented in this study is fit for purpose within the doping-control framework. At 4 and 22 °C, alexamorelin, AOD9604, buserelin, hGH 176-191, kisspeptin-10 and LHRH were extensively degraded after one week in serum and plasma, whereas BPC-157, TB500, vasopressin, lypressin, and terlipressin showed complete degradation only in serum. In contrast, in dried matrices all compounds remained detectable throughout the entire duration of the study, indicating that samples can be transported and stored under non-refrigerated conditions, thereby reducing costs."

Journal

Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. (PubMed, Pain) - "Using LAT8881, a novel peptide ligand for LanCL1, we confirm a key role for LanCL1 in chronic neuropathic sensitisation, with little effect on inflammatory hypersensitivity or physiological nociception...Immunohistochemical analysis revealed a functional reorganisation of LanCL1 in neuropathic models, with reduced cytosolic expression in the DRG and increased expression in satellite glia. These findings establish LanCL1 as a critical mediator of neuropathic hypersensitivity and a prime target for clinical translation."

Journal • Immunology • Neuralgia • Pain

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. (PubMed, Sports Med) - "Our objective is to present the pharmacological mechanisms, safety profiles, and regulatory status of prominent approved and unapproved peptides marketed direct to patients, including AOD-9604 (anti-obesity drug 9604), BPC-157 (body protection compound 157), CJC-1295, FS-344 (follistatin-344), GHK-Cu (glycyl-L-histidyl-L-lysine copper), ipamorelin, MOTS-C (mitochondrial ORF of the 12S rRNA type-c), sermorelin, SS-31 (elamipretide), tesamorelin (Egrifta), Tβ4 (thymosin beta-4), and TB-500 (thymosin beta-4 fragment). We provide a framework to navigate patient discussions about peptides to better facilitate evidence-based practices for musculoskeletal healing and athletic performance. We also discuss the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect."

Journal • Review • Genetic Disorders • Musculoskeletal Diseases • Obesity • TMSB4X

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (PubMed, J Am Acad Orthop Surg Glob Res Rev) - "Wound-healing peptides such as BPC-157, TB-500, and GHK-Cu promote angiogenesis, integrin-mediated extracellular matrix remodeling, and fibroblast activation, whereas growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. Although preclinical studies are promising, there is a current lack of clinical trials. This review integrates current mechanistic insights with orthopaedic relevance, emphasizing safety, efficacy, and future directions for responsible integration into musculoskeletal care."

Journal • Review • Inflammation • Musculoskeletal Diseases • Orthopedics • AMPK • IGF1 • MET • TGFB1

Lat peptides, non-opioid therapeutic candidates for neuropathic pain (NeuPSIG 2025) - "Collectively, this data suggests that the function and viability of stressed sensory neurons is positively impacted by acute treatment with LAT8881. Further work is needed to establish the mechanistic link between LanCL proteins, the neuronal effects and relief of neuropathic pain hypersensitivity."

CNS Disorders • Neuralgia • Pain

Cumulative benefits from chronic subcutaneous dosing of the lat peptides in a rodent model of neuropathy (NeuPSIG 2025) - "Background & Aims: The LAT peptides (e.g. LAT8881), acting via a novel target, the LanC-like (LanCL) protein family, have demonstrated analgesic properties following single administration in rodent neuropathic pain models and clinical proof-of-concept in patients with chronic lumbar radicular pain (LRP).Here we report on studies with the LAT peptides aimed at: a) excluding interactions with opioid receptors or other biological targets that may lead to abuse or dependence, b) investigating any unintended changes in behavioural or physiological state in rodents, and c) investigating analgesia following chronic daily subcutaneous (SC) dosing in the rat L5 spinal nerve ligation model (Chung model). The in vitro functional screens included assays against: (i) 78 GPCR, enzyme, ion channel, neurotransmitter transporters, and nuclear hormone receptors at 10 concentrations across 4 log orders, (ii) µ-, κ-, and δ-opioid receptors in agonist, antagonist and positive..."

Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain

Putative Plasma PD Biomarkers Identified from Clinical Study of LAT8881 in Lumbar Radicular Pain (IASP 2024) - "Having demonstrated clinical "proof-of-concept" of LAT8881 as a novel first-in-class therapeutic for the treatment of neuropathic pain, proteomic analysis of plasma samples taken from the study subjects has identified a number of differentially expressed proteins in LAT8881 treated subjects, particularly at 1 hour post-dosing. These results could provide the foundation for a pharmacodynamic assay of LanCL target engagement, which would aid screening of potential LAT therapeutics and support investigations into optimal dosing of these therapeutics in future clinical trials. We also observed differences between healthy volunteers and LRP subjects in expression of a number of proteins, including CRP; a larger sample size (only samples from 3 healthy volunteers were included in this analysis) may be more informative."

Biomarker • Clinical • Inflammation • Neuralgia • Pain • CRP

Harnessing endogenous peptide compounds as potential therapeutics for severe influenza. (PubMed, J Infect Dis) - "These findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage."

Journal • Infectious Disease • Inflammation • Influenza • Otorhinolaryngology • Pneumonia • Pulmonary Disease • Respiratory Diseases

Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials. (PubMed, Int J Mol Sci) - "A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets: Angiotensin Type 2 Receptor (AT2R) antagonism (olodanrigan), Voltage-Gated Calcium Channel (VGCC) α2δ subunit inhibition (crisugabalin, mirogabalin and pregabalin), Voltage-Gated Sodium Channel (VGSC) blockade (funapide and lidocaine), Cyclooxygenase-1 (COX-1) inhibition (TRK-700), Adaptor-Associated Kinase 1 (AAK1) inhibition (LX9211), Lanthionine Synthetase C-Like Protein (LANCL) activation (LAT8881), N-Methyl-D-Aspartate (NMDA) receptor antagonism (esketamine), mu opioid receptor agonism (tramadol, oxycodone and hydromorphone) and Nerve Growth Factor (NGF) inhibition (fulranumab). AT2R antagonism, AAK1 inhibition, LANCL activation and NGF inhibition are considered first-in-class analgesics. Hopefully, these trials will result in a better clinical management of PHN."

Journal • Review • Neuralgia • Pain

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - P1 | N=25 | Completed | Sponsor: Lateral Pharma Pty Ltd | Recruiting ➔ Completed

Trial completion • Pain

Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection. (PubMed, Clin Transl Immunology) - "LAT8881 treatment in combination with the antiviral oseltamivir phosphate led to more pronounced reduction in markers of disease severity than treatment with either compound alone. These studies provide the first evidence identifying LAT8881 and LAT9991F as novel host-protective therapies that improve survival, limit viral replication, reduce local inflammation and curtail tissue damage during severe IAV infection. Evaluation of LAT8881 and LAT9991F in other infectious and inflammatory conditions of the airways is warranted."

Journal • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Influenza • Obesity • Osteoarthritis • Pain • Pulmonary Disease • Respiratory Diseases • Rheumatology

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Lateral Pharma Pty Ltd | Trial completion date: Nov 2022 ➔ Jun 2023 | Trial primary completion date: Sep 2022 ➔ Mar 2023

Trial completion date • Trial primary completion date • Pain

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - P1 | N=28 | Recruiting | Sponsor: Lateral Pharma Pty Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Pain

A Two-part Proof-of-Concept Study Assessing the Safety and Efficacy of LAT8881 in Lumbar Radicular Pain (clinicaltrials.gov) - P1 | N=28 | Not yet recruiting | Sponsor: Lateral Pharma Pty Ltd

New P1 trial • Pain

Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - P2a; N=52; Completed; Sponsor: Lateral Pharma Pty Ltd; Active, not recruiting ➔ Completed

Clinical • Trial completion • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine (clinicaltrials.gov) - P2; N=26; Completed; Sponsor: Lateral Pharma Pty Ltd; Recruiting ➔ Completed

Clinical • Trial completion • CNS Disorders • Migraine

Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - P2a; N=55; Active, not recruiting; Sponsor: Lateral Pharma Pty Ltd; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine (clinicaltrials.gov) - P2; N=26; Recruiting; Sponsor: Lateral Pharma Pty Ltd

Clinical • New P2 trial

Oral LAT8881 in Neuropathic Pain (clinicaltrials.gov) - P2a; N=55; Recruiting; Sponsor: Lateral Pharma Pty Ltd; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open